ASX:ACW Actinogen Medical (ACW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Actinogen Medical Stock (ASX:ACW) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Actinogen Medical alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume275,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield8.76%Price TargetN/AConsensus RatingN/A Company OverviewActinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive ACW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinogen Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ACW Stock News HeadlinesActinogen Medical’s Promising Advances in Neurological TreatmentsNovember 14, 2024 | markets.businessinsider.comActinogen receives $9M R&D tax rebate to fund Alzheimer's trialNovember 12, 2024 | msn.comNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.November 23, 2024 | Darwin (Ad)Actinogen Medical Secures $9 Million R&D Rebate BoostNovember 12, 2024 | markets.businessinsider.comActinogen Medical Expands Shares Amid Drug Development ProgressNovember 4, 2024 | markets.businessinsider.comActinogen Medical Expands Market Presence with New SecuritiesNovember 4, 2024 | markets.businessinsider.comActinogen Medical Advances in Neurological Drug DevelopmentNovember 3, 2024 | tipranks.comActinogen Medical Highlights Alzheimer’s Research ProgressOctober 31, 2024 | markets.businessinsider.comSee More Headlines ACW Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Actinogen Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinogen Medical investors own include Vocus Group (VOC), Oncolytics Biotech (ONCY), Chorus (CNU), BioSig Technologies (BSGM) and Admedus (AHZ). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryAutomobiles And Trucks Current SymbolASX:ACW CUSIPN/A CIKN/A Webwww.actinogen.com.au Phone61 2 8964 7401FaxN/AEmployees1,766Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net Margins-131.34% Pretax MarginN/A Return on Equity-78.81% Return on Assets-45.37% Debt Debt-to-Equity Ratio1.62 Current Ratio13.91 Quick Ratio13.73 Sales & Book Value Annual Sales$9.93 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.38 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares3,080,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.74 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (ASX:ACW) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinogen Medical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinogen Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
